Cross-reactivity pattern of rash from current aromatic antiepileptic drugs

Epilepsy Research

Volumn 80, Issue 2-3, 2008, Pages 194-200

  Alvestad, Silje ^a   Lydersen, Stian ^a   Brodtkorb, Eylert ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Carbamazepine; Cross reactivity; Lamotrigine; Oxcarbazepine; Phenytoin; Rash

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN;

ANAMNESIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROSS REACTION; DISEASE SEVERITY; EPILEPSY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RASH; STEVENS JOHNSON SYNDROME;

ADOLESCENT; ADULT; ANTICONVULSANTS; CROSS-SECTIONAL STUDIES; EPILEPSY; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 47549087521     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2008.04.003     Document Type: Article

References (26)

1. Agresti A., and Caffo B.A. Simple and effective confidence intervals for proportions and difference of proportions result from adding two successes and two failures. Am. Stat. 54 (2000) 280-288
2. Alvestad S., Lydersen S., and Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 48 (2007) 1360-1365
3. Anderson G.D. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 43 Suppl. 3 (2002) 53-59
4. Arif H., Buchsbaum R., Weintraub D., Koyfman S., Salas-Humara C., Bazil C.W., Resor S.R., and Hirsch L.J. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68 (2007) 1701-1709
5. Bavdekar S.B., Muranjan M.N., Gogtay N.J., Kantharia V., and Kshirsagar N.A. Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment. Ann. Pharmacother. 38 (2004) 1648-1650
6. Bigby M., Jick S., Jick H., and Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive patients, 1975 to 1982. Toxicology 256 (1986) 3358-3363
7. Friis M.L., Kristensen O., Boas J., Dalby M., Deth S.H., Gram L., Mikkelsen M., Pedersen B., Sabers A., and Worm-Petersen J. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol. Scand. 87 (1993) 224-227
8. Hirji K.F. Exact Analysis of Discrete Data (2006), Chapman & Hall/CRC, Boca Raton pp. 218-219
9. Hirsch L.J., Weintraub D.B., Buchsbaum R., Spencer H.T., Straka T., Hager M., and Resor Jr. S.R. Predictors of lamotrigine-associated rash. Epilepsia 47 (2007) 318-322
10. Hung S.-I., Chung W.-H., Jee S.-H., Chen W.-C., Chang Y.-T., Lee W.-R., Hu S.-L., Wu M.-T., Chen G.-S., Wong T.-W., Hsiao P.-F., Chen W.-H., Shih H.-Y., Fang W.-H., Wei C.-Y., Lou Y.-H., Huang Y.-L., Lin J.-J., and Chen Y.-T. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16 (2006) 297-306
11. Hyson C., and Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can. J. Neurol. Sci. 24 (1997) 245-249
12. Klassen B.D., and Sadler R.M. Induction of hypersensitivity to a previously tolerated antiepileptic drug by a second antiepileptic drug. Epilepsia 42 (2001) 433-435
13. Knowles S.R., Shapiro L.E., and Shear N.H. Anticonvulsant hypersensitive syndrome. Incidence, prevention and management. Drug Saf. 6 (1999) 489-501
14. Krämer G. Oxcarbazepine. Adverse effects. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott Williams & Wilkins, Philadelphia 479-486
15. Lu W., and Uetrecht J.P. Possible bioactivation pathways of lamotrigine. Drug Metab. Dispos. 35 (2007) 1050-1056
16. Maggs J.L., Naisbitt D.J., Tettey J.N.A., Pirmohamed M., and Park B.K. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem. Res. Toxicol. 13 (2000) 1075-1081
17. Mockenhaupt M., Messenheimer J., Tennis P., and Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 64 (2005) 1134-1138
18. Naisbitt D.J., Farrell J., Wong G., Depta J.P., Dodd C.C., Hopkins J.E., Gibney C.A., Chadwick D.W., Pichler W.J., Pirmohamed M., and Park B.K. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J. Allergy Clin. Immunol. 111 (2003) 1393-1403
19. Park B.K., Naisbitt D.J., Gordon S.F., Kitteringham N.R., and Pirmohamed M. Metabolic activation in drug allergies. Toxicology 158 (2001) 11-23
20. Romano A., Pettinato R., Andriolo M., Viola M., Gueant-Rodriguez R.M., Valluzzi R.L., Romano C., Elia M., Ventura M.T., and Gueant J.L. Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr. Pharm. Des. 2 (2006) 3373-3381
21. Roujeau J.-C. Immune mechanisms in drug allergy. Allergol. Int. 55 (2006) 27-33
22. Schmidt D., and Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav. 1 (2000) 396-405
23. Wong I.C., and Lhatoo S.D. Adverse reactions to new anticonvulsant drugs. Drug Saf. 23 (2000) 35-56
24. Wong I.C., Mawer G.E., and Sander J.W. Factors influencing the incidence of lamotrigine-related skin rash. Ann. Pharmacother. 33 (1999) 1037-1042
25. + T-cell clones from patients with carbamazepine hypersensitivity. J. Allergy Clin. Immunol. 119 (2007) 973-981
26. Zaccara G., Franciotta D., and Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48 (2007) 1223-1248